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The COVID-19 pandemic resulted in the introduction of stringent control measures such as 
travel restrictions, isolation and interruption of health care services.  
Leprosy is a stigmatised, neglected tropical disease which if undiagnosed leads to 
permanent disability. We describe the results of an online survey of leprosy services 
provided by referral centres during the COVID-19 pandemic. We found great efforts were 
made to maintain services however availability of services and access to them was reduced. 
The interruption of diagnostic and treatment services is likely to lead to delayed in diagnosis 




Introduction:  The COVID-19 pandemic has led to governments implementing a variety of 
public health measures to control transmission and has affected health services, economies 
and social cohesion. Leprosy is a complex, communicable neglected tropical disease (NTD) 
caused by Mycobacterium leprae and it remains an important health problem in low and 
middle-income countries (LMICs). The natural history of leprosy means that affected 
individuals need long-term follow up. The measures recommended to reduce transmission of 
SARS-CoV-2 such as isolation, social distancing and the restriction on movement can create 
barriers to health services. We evaluated the impact of the COVID-19 epidemic response on 
leprosy services and disease management. 
 
Methods: We conducted a cross-sectional online survey with health care professionals in 
leprosy referral centres. 
 
Results: Eighty percent of leprosy diagnostic services were reduced. All respondents reported 
that multi-drug therapy (MDT) was available but two reported reduced stock. Sixty-six 
percent of respondents reported that patients could access MDT during social restrictions, 
57% of respondents reported patients obtained MDT in their local clinic. Clinicians used 
alternative strategies such as telephone consultations to maintain contact with patients. 
However, patients were not able to travel to the referral centres. Other services such as 
reconstructive surgery were closed.   
 
Discussion: This study highlights the effects of the initial phase of the SARS-CoV-2 pandemic 
on leprosy services in a range of leprosy endemic countries. Many services remained open 
providing leprosy diagnosis, MDT and leprosy reaction medications. Referral centres 
developed innovative measures such as telemedicine tools to counter the negative impact of 





Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is reported to have caused 
more than 103,943,000 infections and 2,255,000 deaths1 by February 2021. The pandemic 
has led to governments implementing a variety of public health measures to control 
transmission and has affected health services, economies and social cohesion. Epidemics can 
lead to severe impact on health services. The Ebola virus disease (EVD) outbreak 2014-16 was 
associated with a high mortality and had a devastating effect on healthcare workers and 
healthcare service delivery2 in West Africa. It is estimated that deaths due to HIV, malaria and 
tuberculosis increased3. Maternal and neonatal mortality had significantly increased4,5 and 
reduced access to services affected those with chronic non-communicable diseases(NCD)6. 
 
Leprosy is a complex, communicable neglected tropical disease (NTD) caused by 
Mycobacterium leprae which has chronic features giving it similarities to NCDs7. Leprosy 
remains an important health problem in low and middle-income countries (LMICs) and 
202,185 new cases of leprosy were reported to WHO in 20198. India reported the largest 
number of new cases, followed by Brazil and Indonesia8. Leprosy causes a range of clinical 
presentations and if not diagnosed early can lead to permanent disability9. Multi-drug therapy 
(MDT) is an effective combination of three antimicrobials, rifampicin, clofazimine and 
dapsone, provided free to patients10. MDT is prescribed for 6 or 12 months. However, even 
with successful treatment, individuals are at risk of developing leprosy immune-mediated 
complications known as “reactions” which are a risk factor for permanent nerve damage and 
may be associated with increased mortality11–14. Reactions require immunosuppression 
usually with oral corticosteroids which cause adverse effects. The natural history of leprosy 
means that affected individuals need long-term follow up. 12–14. 
 
The measures recommended to reduce transmission of SARS-CoV-2 such as isolation, social 
distancing and the restriction on movement create barriers to accessing health care in 
addition to those normally present. NTDs disproportionately affect the most socially and 
economically  vulnerable individuals in LMICs, who already experience considerable barriers 
to access health services15,16. The fear of SARS-CoV-2 infection, reduced availability of services 
due to restructuring of health care provision or reduced staffing may limit access or result in 
the closure of services.   
 
WHO issued interim guidance for implementation of NTD programmes (including leprosy) on 
1st of April 2020 which recommended the postponement of NTD surveys, active surveillance 
activities and community campaigns17. In July 2020, guidelines were published 
recommending risk assessment and thorough planning to restart only essential activities18.  
The impact of service interruptions on NTD control and disability is unknown. 
 
We evaluated the COVID-19 epidemic response, the impact of COVID-19 on leprosy services 
and disease management, and mechanisms of support available for the clients of leprosy 




A cross-sectional online survey was conducted between 19th May and 7th July 2020. A short, 
structured, online questionnaire comprising of 6 sections with 54 questions was designed 
using REDCap (Appendix 1). The responses were a combination of multiple choice and free 
text responses. The themes of the questions in the six sections were leprosy service provision, 
treatment of leprosy during COVID-19, COVID-19 information and control measures, COVID-
19 diagnosis, management and precautions, COVID-19 among patients with leprosy and 
financial support. 
 
The London School of Hygiene & Tropical Medicine Observational / Interventions Research 
Ethics Committee advised that no ethical approval was necessary because this work is a 





The members of the ENLIST Group (a network of leprosy collaborating centres)19, based in 
institutions supported by LEPRA20, a UK based charity which supports leprosy work in 
Bangladesh, India, Mozambique and Zimbabwe and other leprologists from our networks 
were invited to participate.  
 
The invitation was distributed by email with the link to the online questionnaire. All 
participants were informed of the objectives of the evaluation.  
 
Data Analysis 




Forty-four invitations to complete the survey were sent to individuals working at institutions 
in Bangladesh, Brazil, Democratic Republic of Congo (DRC), Ethiopia, India, Indonesia, Nepal, 
Nigeria, Sri Lanka and the United States of America.  
 
Twenty-one completed responses were obtained from centres in Bangladesh (n=3), Brazil 
(n=4), DRC (n=2), Ethiopia (n=1), India (n=8), Indonesia (n=1), Nigeria (n=1) and Sri Lanka 
(n=1).  
 
Leprosy Service Provision 
 
There was variation between centres in the range of services provided. All respondents 
reported some disruption to their services such as surgical services and community-based 
activities.  
 
Table 1 shows the services normally provided and the extent they were affected (not affected, 
reduced, closed). Sixteen of twenty (80%) leprosy diagnostic services were reduced, and only 
one (5%) closed. All respondents reported that MDT drugs were available but two (13%) 
reported reduced stock.  
 
Respondents highlighted that treatment was available but factors such as restrictions on 
travel changed working practices. 
 
“Patient movement is restricted due to lockdown situation, so MDT blister is handed 
over to each patient for 2 - 3 months together.” 
 
Seven of eight (87%) reconstructive surgery services suspended their activities. Community-
based activities, such as active case finding, and delivery of single-dose rifampicin 
chemoprophylaxis to the contacts of leprosy patients, were suspended by 76.9% and 66.7% 
of the services respectively.  
 
Six respondents reported suspension of other activities such as slit skin smear (n=1), ulcer 
management (n=2), rehabilitation (n=2), counselling (n=1), community-based rehabilitation 
(n=1), income generation activities (n=1), training of medical officers and community health 
care workers (n=2), academic activities (n=1), and research (n=2).  
 
The changes to services were communicated to service users: 
 




Table 1.Leprosy services availability during the COVID-19 pandemic 
Institutional impact 
Service normally  
provided (n) 
Service not 
affected n (%) 
Reduced service 
n (%) 
Service closed n 
(%) 
Not answered  
n (%) 
Leprosy Diagnosis 
(20) 3 (15.0) 16 (80.0) 1(5.0) - 
MDT provision (15)* 13 (86.7) 2(13.3) 0 - 
MDT access (15)  7 (46.7) 6 (40) 2(13.3) - 
Reaction clinic (18) 5 (27.8) 12 (66.7) 1 (5.6) - 
Reaction inpatient 
(18) 5(27.8) 5 (27.8) 2 (11.1) 6 (33.3) 
Physiotherapy (18) 1 (11.1) 12 (66.7) 3 (16.7) 1 (5.6) 
Orthotics (13) 4 (30.8) 7 (53.8) 2 (15.4) - 
Reconstructive 
surgery (8) 1 (12.5) 0 7 (87.5) - 
Active case finding 





0 1(33.3) 2 (66.7) - 
* MDT provision was characterised as not affected, reduced stock or out of stock. 
 
Only one respondent reported staff absence due to COVID-19 illness. Five centres had their 
staff re-deployed to the pandemic response activities.  
 
Treatment of leprosy during COVID-19 
 
Table 2 shows responses concerning treatment access. Fourteen of 21 (66.7%) respondents 
reported that patients could access MDT during social restrictions, 12 (57%) respondents 
reported patients obtained MDT in their local clinic. Only 11 (52%) respondents reported that 
reaction medication was provided in local clinics. 
 
Table 2. The accessibility of MDT and drug therapy for leprosy reactions during COVID-19 pandemic in leprosy referral 
centers  
Question NUMBER OF CENTRES (n=21) 
YES NO NO RESPONSE 
Can most patients obtain MDT during social 
restrictions? 14 (66.7%) 4 (19%) 3 (14.3%) 
Can most patients obtain MDT in your institution? 11 (73.3%) 2 (13.3%) 2 (13.3%) 
Can most patients obtain MDT in their local clinic? 12 (57.1%) 6 (28.6%) 3 (14.3%) 
Were patients taking a larger MDT supply than 
normal? 10 (66.7%) 4 (26.7%) 1 (6.1%) 
Can most patients obtain reaction medication during 
lockdown? 12(66.6%) 4(22.2%) 2(11.1%) 
Can most patients obtain reaction medication in 
your institution? 13(72.2%) 3(16.7%) 2(11.1%) 
Were patients taking reaction medication given a 
larger supply? 8(72.2%) 5(27.8%) 5(27.8%) 
Can most patients obtain reaction medication in 
their local clinic? 11(52.4%) 7(33.3%) 3(14.3%) 
 
Eighteen respondents (85%) reported provision of reaction medication, all of them provided 
corticosteroids, seven (38%) provided thalidomide, nine (50%) provided clofazimine and 3 
(17%) provided other reaction medications such as methotrexate and azathioprine. 
Thalidomide supply was not affected, however in one centre patients were unable to collect 
the medication. Clofazimine supply was reduced in two (22%) centres, and out of stock in one 
centre (11%).  
 
The supply of oral corticosteroids was reported to be reduced at two centres (11%) because 
of the impact of the pandemic. Overall, five respondents (28%) stated that patients were 
unable to collect medication. The difficulty in maintaining supply of reaction medications is 
characterised in the following quote: 
 
“Anti-inflammatory drugs availability affected as the drug was in short supply and 
supply could not be ensured due to restricted transport in view of lockdown.” 
 
The responses about arrangements for monitoring patients during social and travel 
restrictions showed that clinicians at 15 of 21 (71%) centres contacted patients by telephone. 
All centres developed strategies to remotely support the welfare of leprosy patients such as 
actively contacting vulnerable individuals, establishing telephone helplines, or via social 
media platforms, such as WhatsApp.  This innovation was described by one respondent as: 
 
“We are providing medical orientation about treatment with the patients via 
WhatsApp.” 
 
All respondents described reduced attendance by patients due to transport and travel 
restrictions.  
 
“Travel restriction have been the hugest issue limiting travel for patients and pushing 
us to think of ways of doing things by distance.” 
 
Thirteen of twenty-one (62%) respondents reported providing a written summary of the 
diagnosis and treatment to their patients should the need arise for them to consult a 
healthcare professional or person in authority about their condition. 
 
COVID-19 public information and control measures 
 
Public information about COVID-19 was available through a variety of media: TV, radio, 
posters and social media platforms such as Facebook and Twitter. All respondents reported 
some kind of restriction measures implemented by local or national authorities, 17 of 21 
(81%) respondents reported measures including social distance, use of masks in public places, 
shielding of vulnerable individuals, travel restrictions and curfews. 
 
Eleven respondents (52%) reported COVID-19 information produced specifically for leprosy 
patients by a variety of agencies: WHO country office (n=3), Ministry of Health (n=2), leprosy 
or other specialist professional society (n=2), International Federation of Anti-Leprosy 
Associations (ILEP)/ ILEP Technical Committee (ITC) document (n=3) or produced by clinicians 
at the institution (n=3).  
 
COVID-19 diagnosis, management and precautions 
 
The criteria used to diagnose COVID-19 varied amongst the respondents. Seven centres (33%) 
reported the use of clinical criteria: symptoms, signs and low oxygen saturation. Various tests 
of infection were reported to be available: nasal/throat swab PCR tests (n=18), ELISA serology 
tests (n=5) and point of care tests (n=3). In five centres both PCR and serology tests were 
available. 
 
Measures to reduce the risk of transmission of SARS-CoV-2 in leprosy clinics were described 
in the majority of organisations. All but two centres recommended some personal protective 
equipment (PPE): masks (n=14), surgical masks (n=11), Filtering Face Piece 3 (FFP3) or N95 
respirators (n=9), visors or goggles (n=9), aprons (n=8), gowns (n=6), disposable gloves (n=14). 
 
“We spaced the appointment time and guided the use of masks to all patients of the 
institution.” 
 
COVID-19 patients were managed at six of the centres (28%) which provided general medical 
care as well as leprosy services. 
 
COVID-19 and leprosy patients   
 
Six individuals with leprosy at five of the 21 (23.8%) centres had been diagnosed with COVID-
19. No deaths related to COVID-19 in this group were reported. One respondent expressed 
surprise about the low numbers of leprosy patients affected: 
 
“… we are surprised that patients in use of prednisone and thalidomide are not been 
widely affected by COVID-19.” 
 
The respondents expressed concern about immunosuppression for the management of 
leprosy reactions exacerbating SARS-CoV-2 infection. 
 




Financial support was provided for leprosy affected individuals to mitigate the effects of 
COVID-19, in all countries but one country, by a variety of agencies both governmental (n=8) 
and non-governmental (n=3) including affected persons organisations (n=1). Funds were also 
raised by voluntary contributions from communities (n=8) to provide such financial support. 
One respondent outlined various strategies including food donation, obtaining masks and 




This study highlights the impact of the initial phase of the SARS-CoV-2 pandemic on leprosy 
services in a range of leprosy endemic countries. Many services remained open providing 
leprosy diagnosis, MDT and leprosy reaction medications. However, patients were not able 
to travel to the centres. Other services such as reconstructive surgery were closed. Referral 
centres developed innovative measures to counter the negative impact. Our data confirms 
the concerns of researchers and organisations regarding the impact of COVID-19 on NTDs21 
including leprosy22–24. Mahato emphasised the impact of social distancing, travel restrictions 
and lockdown measures on health care access, community activities and stigma on leprosy 
affected individuals in Nepal24.  
 
COVID-19 and the public health measures implemented created barriers to the access of 
leprosy services due to difficulties in travelling to centres for care and reduced or closed 
services. There was a reduction of all services essential to the case management of leprosy 
and other strategic interventions outlined in the WHO NTD Roadmap both clinic and 
community -based25. Community activities are not only important for early case detection but 
also facilitate the reduction in stigma and promote wellbeing for affected individuals and their 
families.  
 
MDT and drugs used to treat leprosy reactions were mostly available in the referral centres 
and some at local healthcare facilities. Travel restrictions suggest that more individuals would 
need to rely on local services to provide essential care such as diagnosis and management. 
Reduced access to leprosy care, due to COVID-19 will result in additional delay in the diagnosis 
of leprosy and complications. The closure of inpatient services for the management of leprosy 
reactions has a greater impact when there are travel restrictions in settings where patients 
have to travel considerable distances. The chronic complications of leprosy such as 
neuropathic ulceration and osteomyelitis left untreated lead to loss of tissue and function. It 
may be that on resumption of normal activity there may be a more severe burden of such 
complications requiring treatment. A survey of National Leprosy Programme managers 
initiated in April 2020 by the Global Partnership for Zero Leprosy (GPZL) reported that 34 
respondents highlighted similar issues concerning MDT supply and access, reaction 
medication and ulcer and disability care26. 
 
Travel restrictions and health systems focussing on treatment and control of COVID-19 has 
resulted in reduced detection of leprosy and may result in an increase burden of disability in 
the coming years.27 
 
Before the pandemic, in one cohort, 40% of multibacillary patients with normal nerve 
function at the time of diagnosis of leprosy developed leprosy reactions and/or nerve function 
impairment which required prompt management28. The expertise to diagnose leprosy 
reactions and institute treatment is not widely available and may lead to delay which 
increases the risk of permanent nerve damage and disability29. In individuals already 
established on MDT and/or leprosy reaction treatment it is uncertain whether monitoring for 
adverse effects would be maintained. There is the potential for those on long-term 
corticosteroids to experience an interruption of treatment with the risk of severe adrenal 
insufficiency. A consultation process with leprosy affected individuals and their organisations 
was conducted by the GPZL in April and May 2020. It received no reports of patients being 
provided with extended courses of rection medication in contrast to some National Leprosy 
Programme representatives reporting dispensing up to three month’s supply of MDT30.  
 
Our non-systematic data of low numbers of leprosy service users being affected by COVID-19 
is in keeping with retrospective data from Brazil during the same period31.  However, Santos 
and colleagues reported that all four of leprosy affected individuals died due to COVID-19 in 
contrast with the six reported by our respondents. None of these ten cases were associated 
with leprosy reactions. Antunes and colleagues32 postulated that SARS-CoV-2 infection may 
trigger leprosy reactions but data supporting this has not yet emerged.  The restricted access 
to diagnosis and no requirement for reporting leprosy reactions means there may be no 
conclusive answer. 
 
We are not aware of any reports of a significant association between severe COVID-19 and 
treatment for leprosy reactions despite this being a concern of our respondents and 
others33,34. Interestingly, a report of nosocomially acquired SARS-CoV-2 infection in a 26 year-
old man with ENL treated with methotrexate and systemic corticosteroids describe a mild 
COVID-19 illness and favourable outcome35. Since our data were collected, short course 
dexamethasone has been shown to reduce mortality in hospitalized patients with COVID-1936. 
 
The responses to our questionnaire illustrate innovative strategies and versatility employed 
by oganisations providing services to leprosy affected individuals. The frequency of clinic visits 
was reduced, medical summaries were given to patients and MDT was supplied for longer 
periods. The use of technology to facilitate telemedicine and provide non-clinical support to 
service users demonstrates a potential positive impact of the COVID-19 pandemic37. The 
incorporation of some adaptations of service delivery may have long-term benefits to service 
users, staff and organisations.   
 
The limitations of our study are that it was conducted in the early phase of the COVID-19 
pandemic and data were only provided on a single occasion. Respondents may not have 
included important examples of the impact of COVID-19 that were not specifically covered by 
the questions in the survey. The respondents’ organisations provide leprosy services in 
referral settings and so we are unable to provide a complete picture of the impact of COVID-
19 on leprosy in local settings. Nevertheless, we have gathered data from clinical settings in 
a wide variety of leprosy endemic settings which demonstrate the impact of COVID-19 on 
services and the changes required to meet a range of challenges.  
 
The development of efficacious vaccines against SARS-CoV-2 is very welcome, however, it is 
unclear when these will be widely available in many leprosy endemic settings38. Leprosy 
services have been identified among essential services that should be protected during the 
COVID-19 pandemic39. 
 
The maintenance of essential leprosy services and minimising barriers to access of services 
needs to be a priority for all agencies involved in their delivery. Measures to combat the 
transmission of COVID-19 will be necessary for the foreseeable future. Our data complements 
those generated by the GPZL. The need for continued advocacy is required to ensure policy 
makers are aware of the disproportionate impact public health measures may have on 
economically vulnerable and stigmatised individuals who need access to long-term health 
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